Skip to main content

Market Overview

Amid Papa's Appointment, Rodman & Renshaw Still Buying Valeant

Amid Papa's Appointment, Rodman & Renshaw Still Buying Valeant

On April 25, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) announced that the former CEO of Perrigo Company plc Ordinary Shares (NYSE: PRGO), Joseph Papa, would replace the outgoing Mike Pearson as chairman and CEO.

Rodman & Renshaw’s Raghuram Selvaraju reiterated a Buy rating on Valeant Pharma, with a price target of $105.

Papa Takes Over

The company expects Papa to take over as chairman and CEO in early May 2016.

Related Link: Who Is Joe Papa?

Selvaraju mentioned that Papa was a good choice, given his long track-record in the pharma sector, wide experience in the management of diversified businesses and multiple product lines, as well as robust relationships with reimbursement agencies and pharmacy benefit managers.

“From our perspective, Mr. Papa could potentially reinvent the corporate culture at Valeant and turn the struggling company around,” the analyst stated.

A Positive Change

Selvaraju also pointed out that Valeant Pharma possessed a portfolio of attractively positioned business units and products, and with expectations having been meaningfully reduced for the company through the past several months, the bar has been set very low for Papa.

Selvaraju also believes that the incoming CEO “possesses significantly better public relations skills than Mr. Pearson, whose communications with the public had historically been something of an Achilles heel for Valeant.”

Therefore, Papa taking over the reins was likely to bring about a sea change at the company that had the potential to drive meaningful shareholder value accretion.

Latest Ratings for VRX

Jun 2018TD SecuritiesDowngradesBuyHold
Jun 2018BarclaysUpgradesEqual-WeightOverweight
May 2018MizuhoUpgradesNeutralBuy

View More Analyst Ratings for VRX
View the Latest Analyst Ratings


Related Articles (PRGO + VRX)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas News Reiteration Management Analyst Ratings Trading Ideas Best of Benzinga

Latest Ratings

ETCredit SuisseMaintains13.0
IFRXCredit SuisseMaintains2.8
METCredit SuisseMaintains68.0
FLXNCredit SuisseMaintains14.0
ENPHCapital OneInitiates Coverage On175.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at